Price
No data yet.
Social Signal Score
Analyst Ratings
14 analystsRevenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Michael Thomas Henderson
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 261
- Beta
- 0.34
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- 34.89
Financials
Net Income
$-85.85MEBITDA
$-84.20MFree Cash Flow
$-71.38MEPS (diluted)
$-1.14Shares Outstanding (diluted)
75.44M+48.9%Operating Expenses
$91.64MCash & Debt
$971.93MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-255.84M | $-4.22 |
| 2024 | $0.00 | $-182.15M | $-3.30 |
| 2023 | $0.00 | $-83.98M | $-1.66 |
| 2022 | $0.00 | $-39.78M | $-0.79 |
Valuation
APGEhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100+13.64%Social Signal Score
Mentions (3)
- News (RSS)yahoo·27d ago·Neutral
Apogee (APOG) Agreed to Acquire GroGlass for Up to €62.5M. Can a High-Margin Niche Deliver the Promised Synergies?
View source ↗ - News (RSS)investing·40d ago·Neutral
Apogee Therapeutics stock hits all-time high at 134.89 USD
View source ↗ - Newsbenzinga.com·54d ago·Negative
This Apogee Therapeutics Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
View source ↗
Earnings
Mon, Nov 9(in 5 weeks)
Consensus estimate $-1.14 per share
Typical surprise +0.9% (median, so one quarter with a near-zero estimate can't distort it)
- Mon, Aug 10$-1.14 vs $-1.07miss
- Mon, May 11$-1.06 vs $-1.07beat
- Mon, Mar 2$-1.03 vs $-1.05beat
- Mon, Nov 10$-1.11 vs $-1.12beat
- Mon, Aug 11$-1.13 vs $-1.03miss
- Mon, May 12$-0.95 vs $-1.19beat
Estimates and results for APGE via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by APGE officers and directors.
- Bought
- —
- Sold
- $26.7m
0 trades
32 trades
- Dambkowski Carlsold
- Henderson Michael Thomassold
- Dambkowski Carlsold
- Dambkowski Carlsold
- Henderson Michael Thomassold
- Henderson Michael Thomassold
- Henderson Michael Thomassold
- Henderson Michael Thomassold
68 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in APGE.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.